US4450150A
(en)
|
1973-05-17 |
1984-05-22 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery depots, and method for preparing and using the same
|
US4232027A
(en)
|
1979-01-29 |
1980-11-04 |
E. R. Squibb & Sons, Inc. |
1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives
|
DE3381783D1
(de)
|
1982-03-03 |
1990-09-13 |
Genentech Inc |
Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
|
EP0272253A4
(fr)
|
1986-03-07 |
1990-02-05 |
Massachusetts Inst Technology |
Procede pour ameliorer la stabilite des glycoproteines.
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
ATE120761T1
(de)
|
1987-05-21 |
1995-04-15 |
Creative Biomolecules Inc |
Multifunktionelle proteine mit vorbestimmter zielsetzung.
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
US6770274B1
(en)
|
1990-09-14 |
2004-08-03 |
The General Hospital Corporation |
Viral mutant HSV mediated destruction of neoplastic cells
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
US5780279A
(en)
|
1990-12-03 |
1998-07-14 |
Genentech, Inc. |
Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
JP3266311B2
(ja)
|
1991-05-02 |
2002-03-18 |
生化学工業株式会社 |
新規ポリペプチドおよびこれを用いる抗hiv剤
|
SG64322A1
(en)
|
1991-05-10 |
1999-04-27 |
Rhone Poulenc Rorer Int |
Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
US5858657A
(en)
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Tech |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
DE4221054A1
(de)
|
1992-06-30 |
1994-01-05 |
Herbst Bremer Goldschlaegerei |
Präparat zur prophylaktischen und therapeutischen Behandlung von Karies sowie Verfahren zum Herstellen desselben
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
DE69334100T2
(de)
|
1992-11-13 |
2007-07-19 |
Immunex Corp., Seattle |
Elk ligand, ein cytokin
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5855885A
(en)
|
1993-01-22 |
1999-01-05 |
Smith; Rodger |
Isolation and production of catalytic antibodies using phage technology
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
CA2148931A1
(fr)
|
1993-10-01 |
1995-04-13 |
Jurg Zimmermann |
Derives pyrimidineamine et leurs procedes de preparation
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
EP0729471A1
(fr)
|
1993-11-19 |
1996-09-04 |
Abbott Laboratories |
Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
|
CN1046944C
(zh)
|
1993-12-17 |
1999-12-01 |
山道士有限公司 |
雷怕霉素类衍生物
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
WO1995024190A2
(fr)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
|
EP1464706A3
(fr)
|
1994-04-15 |
2004-11-03 |
Amgen Inc., |
HEK5, HEK7, HEK8 et HEK11: des récepteurs protéine tyrosine kinase d'analogues de l'EPH
|
EP0682027B1
(fr)
|
1994-05-03 |
1997-10-15 |
Novartis AG |
Dérivés de la pyrrolopyrimidine avec une activité anti-proliférative
|
US5585096A
(en)
|
1994-06-23 |
1996-12-17 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
US6699468B1
(en)
|
1994-06-23 |
2004-03-02 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
US5728379A
(en)
|
1994-06-23 |
1998-03-17 |
Georgetown University |
Tumor- or cell-specific herpes simplex virus replication
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
EP2295415A1
(fr)
|
1995-03-30 |
2011-03-16 |
OSI Pharmaceuticals, Inc. |
Derives de quinazoline
|
EP0819129B1
(fr)
|
1995-04-03 |
2000-08-02 |
Novartis AG |
Derives de pyrazole et leurs procedes de preparation
|
CA2218503C
(fr)
|
1995-04-20 |
2001-07-24 |
Pfizer Inc. |
Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5702892A
(en)
|
1995-05-09 |
1997-12-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Phage-display of immunoglobulin heavy chain libraries
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
AU712193B2
(en)
|
1995-06-09 |
1999-10-28 |
Novartis Ag |
Rapamycin derivatives
|
SI9620103A
(sl)
|
1995-07-06 |
1998-10-31 |
Novartis Ag |
Pirolopirimidini in postopki za njihovo pripravo
|
DE19534177A1
(de)
|
1995-09-15 |
1997-03-20 |
Merck Patent Gmbh |
Cyclische Adhäsionsinhibitoren
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
ATE225343T1
(de)
|
1995-12-20 |
2002-10-15 |
Hoffmann La Roche |
Matrix-metalloprotease inhibitoren
|
AU1441497A
(en)
|
1996-01-23 |
1997-08-20 |
Novartis Ag |
Pyrrolopyrimidines and processes for their preparation
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
PT888353E
(pt)
|
1996-03-15 |
2003-11-28 |
Novartis Ag |
Novas n-7-heterociclil-pirrolo¬2,3-d|pirimidinas e sua aplicacao
|
US5714352A
(en)
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
PL190489B1
(pl)
|
1996-04-12 |
2005-12-30 |
Warner Lambert Co |
Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
EP0907642B1
(fr)
|
1996-06-24 |
2005-11-02 |
Pfizer Inc. |
Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
|
US6258823B1
(en)
|
1996-07-12 |
2001-07-10 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
EP0818442A3
(fr)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
|
TR199900048T2
(xx)
|
1996-07-13 |
1999-04-21 |
Glaxo Group Limited |
Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
|
ES2186908T3
(es)
|
1996-07-13 |
2003-05-16 |
Glaxo Group Ltd |
Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
HUP9903014A3
(en)
|
1996-07-18 |
2000-08-28 |
Pfizer |
Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
|
US5824318A
(en)
|
1996-07-24 |
1998-10-20 |
American Cyanamid Company |
Avirulent herpetic viruses useful as tumoricidal agents and vaccines
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
EP1947183B1
(fr)
|
1996-08-16 |
2013-07-17 |
Merck Sharp & Dohme Corp. |
Antigène de surface de cellule de mammifère; agents chimiques relatifs
|
US6153609A
(en)
|
1996-08-23 |
2000-11-28 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
JP4242928B2
(ja)
|
1996-08-23 |
2009-03-25 |
ノバルティス アクチエンゲゼルシャフト |
置換ピロロピリミジンおよびその製造方法
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
JP4205168B2
(ja)
|
1996-10-02 |
2009-01-07 |
ノバルティス アクチエンゲゼルシヤフト |
ピリミジン誘導体およびその製造法
|
AU4779897A
(en)
|
1996-10-02 |
1998-04-24 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
EP0837063A1
(fr)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
Dérivés de 4-aminoquinazoline
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
DK1500329T3
(da)
|
1996-12-03 |
2012-07-09 |
Amgen Fremont Inc |
Humane antistoffer, der specifikt binder TNF-alfa
|
CA2277100C
(fr)
|
1997-01-06 |
2005-11-22 |
Pfizer Inc. |
Derives de sulfone cyclique
|
TR199901849T2
(xx)
|
1997-02-03 |
2000-02-21 |
Pfizer Products Inc. |
Arils�lfonilamino hidroksamik asit t�revleri.
|
EP0964864B1
(fr)
|
1997-02-05 |
2008-04-09 |
Warner-Lambert Company LLC |
Pyrido 2,3d pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
|
CA2279863A1
(fr)
|
1997-02-07 |
1998-08-13 |
Pfizer Inc. |
Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
|
NZ336836A
(en)
|
1997-02-11 |
2001-02-23 |
Pfizer |
Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6057098A
(en)
|
1997-04-04 |
2000-05-02 |
Biosite Diagnostics, Inc. |
Polyvalent display libraries
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
WO1999007701A1
(fr)
|
1997-08-05 |
1999-02-18 |
Sugen, Inc. |
Derives de quinoxaline tricyclique utiles en tant qu'inhibiteurs de proteine tyrosine kinase
|
ATE263147T1
(de)
|
1997-08-08 |
2004-04-15 |
Pfizer Prod Inc |
Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
|
US6379674B1
(en)
|
1997-08-12 |
2002-04-30 |
Georgetown University |
Use of herpes vectors for tumor therapy
|
JP2001520039A
(ja)
|
1997-10-21 |
2001-10-30 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒト腫瘍壊死因子レセプター様タンパク質、tr11,tr11sv1およびtr11sv2
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
CA2319236A1
(fr)
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Nouveaux homologues recepteurs du facteur necrosant des tumeurs et acides nucleiques codant ceux-ci
|
US6303144B1
(en)
|
1998-02-10 |
2001-10-16 |
Welfide Corporation |
Preparations with controlled release
|
AU756838B2
(en)
|
1998-03-04 |
2003-01-23 |
Bristol-Myers Squibb Company |
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
PT1071752E
(pt)
|
1998-04-21 |
2003-11-28 |
Micromet Ag |
Polipeptidos especificos para cd19xcd3 e suas utilizacoes
|
HUP0103617A2
(hu)
|
1998-05-29 |
2002-02-28 |
Sugen, Inc. |
Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
WO2000002871A1
(fr)
|
1998-07-10 |
2000-01-20 |
Merck & Co., Inc. |
Nouveaux inhibiteurs de l'angiogenese
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
AU760020B2
(en)
|
1998-08-31 |
2003-05-08 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
DK1004578T3
(da)
|
1998-11-05 |
2004-06-28 |
Pfizer Prod Inc |
5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
|
GB2344287A
(en)
|
1998-12-03 |
2000-06-07 |
Ferring Bv |
Controlled release pharmaceutical formulation
|
EP1141338A4
(fr)
|
1998-12-31 |
2002-09-25 |
Arch Dev Corp |
Virus de l'herpes simplex recombinant utile dans le traitement des maladies neoplasiques
|
EP2298311B1
(fr)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase
|
WO2000054795A1
(fr)
|
1999-03-15 |
2000-09-21 |
The Trustees Of The University Of Pennsylvania |
Therapie combinee consistant a administrer un agent chimiotherapeutique et un virus oncolytique pour tuer des cellules cancereuses chez un sujet
|
DE60028740T2
(de)
|
1999-03-30 |
2007-05-24 |
Novartis Ag |
Phthalazinderivate zur behandlung von entzündlichen erkrankungen
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
IL146482A0
(en)
|
1999-06-07 |
2002-07-25 |
Immunex Corp |
Tek antagonists
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
US6764675B1
(en)
|
1999-06-08 |
2004-07-20 |
The Uab Research Foundation |
Herpes simplex virus expressing foreign genes and method for treating cancers therewith
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
ATE376837T1
(de)
|
1999-07-12 |
2007-11-15 |
Genentech Inc |
Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
|
DE60010098T2
(de)
|
1999-08-24 |
2005-03-31 |
Ariad Gene Therapeutics, Inc., Cambridge |
28-epirapaloge
|
UA72946C2
(uk)
|
1999-11-05 |
2005-05-16 |
Астразенека Аб |
Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
|
WO2001037820A2
(fr)
|
1999-11-24 |
2001-05-31 |
Sugen, Inc. |
Formulations pour agents pharmaceutiques ionisables comme acides libres ou bases libres
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
DE60107203T3
(de)
|
2000-01-21 |
2009-07-23 |
Biovex Ltd. |
Herpes-virusstämme für die gentherapie
|
US20020197266A1
(en)
|
2000-02-08 |
2002-12-26 |
Waldemar Debinski |
Immunotherapy using interleukin 13 receptor subunit alpha 2
|
NZ521437A
(en)
|
2000-02-25 |
2004-04-30 |
Immunex Corp |
Integrin antagonists suitable as inhibitors of angiogenesis
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
ATE430742T1
(de)
|
2000-12-21 |
2009-05-15 |
Smithkline Beecham Corp |
Pyrimidinamine als angiogenesemodulatoren
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US7749745B2
(en)
|
2001-03-27 |
2010-07-06 |
Georgetown University |
Viral vectors and their use in therapeutic methods
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
US7771951B2
(en)
|
2001-12-03 |
2010-08-10 |
Amgen Fremont Inc. |
Antibody categorization based on binding characteristics
|
JP2002233610A
(ja)
|
2002-02-18 |
2002-08-20 |
Olympia:Kk |
スロットマシン
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
AU2003279842A1
(en)
|
2002-10-04 |
2004-05-04 |
Microchips, Inc. |
Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
|
CN1513993A
(zh)
|
2002-12-31 |
2004-07-21 |
北京博泰迪生物工程科技开发有限公司 |
中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
|
CA2525717A1
(fr)
|
2003-05-23 |
2004-12-09 |
Wyeth |
Ligand du gitr et molecules et anticorps lies au ligand du gitr et leurs utilisations
|
US7635472B2
(en)
|
2003-05-31 |
2009-12-22 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
|
AU2004255340B2
(en)
|
2003-07-08 |
2008-05-01 |
Novartis Ag |
Use of rapamycin and rapamycin derivatives for the treatment of bone loss
|
EP1660126A1
(fr)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
|
WO2005016252A2
(fr)
|
2003-07-11 |
2005-02-24 |
Ariad Gene Therapeutics, Inc. |
Macrocycles contenant du phosphore
|
AR045134A1
(es)
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
CN1839133A
(zh)
|
2003-08-22 |
2006-09-27 |
阿文尼尔药品公司 |
作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用
|
KR101229731B1
(ko)
|
2003-10-16 |
2013-03-07 |
암젠 리서치 (뮌헨) 게엠베하 |
다중특이적 탈면역화된 cd3-바인더
|
WO2005055808A2
(fr)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
US7728114B2
(en)
|
2004-06-03 |
2010-06-01 |
Novimmune S.A. |
Anti-CD3 antibodies and methods of use thereof
|
WO2006083289A2
(fr)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
|
US7731952B2
(en)
|
2004-06-24 |
2010-06-08 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
ATE463486T1
(de)
|
2004-08-26 |
2010-04-15 |
Pfizer |
Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
|
WO2006044453A1
(fr)
|
2004-10-13 |
2006-04-27 |
Wyeth |
Analogues de la 17-hydroxywortmannine employés en tant qu’inhibiteurs de pi3k
|
CA2599925A1
(fr)
|
2005-03-14 |
2006-09-21 |
Merck & Co., Inc. |
Antagonistes du recepteur du cgrp
|
EP1866339B8
(fr)
|
2005-03-25 |
2021-12-01 |
GITR, Inc. |
Molecules de liaison gitr et leurs utilisations
|
LT2439273T
(lt)
|
2005-05-09 |
2019-05-10 |
Ono Pharmaceutical Co., Ltd. |
Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US20090012085A1
(en)
|
2005-09-20 |
2009-01-08 |
Charles Michael Baum |
Dosage forms and methods of treatment using a tyrosine kinase inhibitor
|
EP1981969A4
(fr)
|
2006-01-19 |
2009-06-03 |
Genzyme Corp |
Anticorps anti-gitr destines au traitement du cancer
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
US7888352B2
(en)
|
2006-12-07 |
2011-02-15 |
Piramed Limited |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
CN101230335B
(zh)
|
2007-01-22 |
2010-08-11 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
CN101230334B
(zh)
|
2007-01-22 |
2011-06-01 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
CN109456410B
(zh)
|
2007-04-03 |
2022-01-28 |
安进研发(慕尼黑)股份有限公司 |
跨物种特异性CD3-ε结合结构域
|
LT2520590T
(lt)
|
2007-04-03 |
2018-09-10 |
Amgen Research (Munich) Gmbh |
Susijusioms rūšims specifinis rišantis domenas
|
JP5302952B2
(ja)
|
2007-04-19 |
2013-10-02 |
ドン・ア・ファーム・カンパニー・リミテッド |
糖調節ペプチドの制御放出に適した生分解性マイクロスフェア組成物及びその製造方法
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
MX338504B
(es)
|
2007-09-12 |
2016-04-20 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
|
CA2701292C
(fr)
|
2007-10-25 |
2015-03-24 |
Genentech, Inc. |
Procede de preparation de composes de thienopyrimidine
|
EP2262837A4
(fr)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Protéines de liaison avec pd-1
|
WO2009127691A1
(fr)
|
2008-04-17 |
2009-10-22 |
Ablynx N.V. |
Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant
|
KR20110044992A
(ko)
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
TGF-β 길항제 다중-표적 결합 단백질
|
CN102149820B
(zh)
|
2008-09-12 |
2014-07-23 |
国立大学法人三重大学 |
能够表达外源gitr配体的细胞
|
DK2356153T3
(en)
|
2008-10-01 |
2016-07-04 |
Amgen Res (Munich) Gmbh |
Bispecific single CHAIN PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
|
WO2010103038A1
(fr)
|
2009-03-11 |
2010-09-16 |
Novo Nordisk A/S |
Variants de l'interleukine 21 se liant de manière antagoniste au récepteur de l'il-21
|
AU2010265933B2
(en)
|
2009-06-26 |
2015-05-14 |
Regeneron Pharmaceuticals, Inc. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
LT3023438T
(lt)
|
2009-09-03 |
2020-05-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antikūnai
|
CN105567699A
(zh)
|
2009-10-30 |
2016-05-11 |
诺维信生物制药丹麦公司 |
白蛋白变体
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
SI2519543T1
(sl)
|
2009-12-29 |
2016-08-31 |
Emergent Product Development Seattle, Llc |
Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
|
WO2012059486A1
(fr)
|
2010-11-01 |
2012-05-10 |
Novozymes Biopharma Dk A/S |
Variants d'albumine
|
MX2013010172A
(es)
|
2011-03-11 |
2013-10-25 |
Amgen Inc |
Metodo de analisis mutacional correlacionado para mejorar anticuerpos terapeuticos.
|
US9133164B2
(en)
|
2011-04-13 |
2015-09-15 |
Innov88 Llc |
MIF inhibitors and their uses
|
US8822417B2
(en)
|
2011-05-05 |
2014-09-02 |
Novozymes Biopharma DIC A/S |
Albumin variants
|
WO2013006795A2
(fr)
|
2011-07-07 |
2013-01-10 |
Humanitas International Foundation |
Compositions antivirales et leurs méthodes d'utilisation
|
EP2753355B1
(fr)
|
2011-09-08 |
2018-10-24 |
New York University |
Virus herpès simplex oncolytique et ses utilisations thérapeutiques
|
WO2013039954A1
(fr)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anticorps anti-gitr
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
WO2013075066A2
(fr)
|
2011-11-18 |
2013-05-23 |
Eleven Biotherapeutics, Inc. |
Protéines ayant une demi-vie et d'autres propriétés améliorées
|
WO2013109904A1
(fr)
|
2012-01-19 |
2013-07-25 |
University Of Miami |
Compositions, procédés et série de traitements contre le cancer et des maladies auto-immunes
|
BR112014018679A2
(pt)
|
2012-03-16 |
2017-07-04 |
Novozymes Biopharma Dk As |
variantes de albumina
|
EP2836482B1
(fr)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions et méthodes pour le traitement du cancer
|
US9441039B2
(en)
|
2012-05-07 |
2016-09-13 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
WO2013169693A1
(fr)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Méthodes destinées à traiter le cancer à l'aide d'un polypeptide il-21 et d'un anticorps anti-pd-1
|
MX2015005363A
(es)
|
2012-11-08 |
2015-11-06 |
Novozymes Biopharma Dk As |
Variantes de albumina.
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
EP2970121B1
(fr)
|
2013-03-15 |
2017-12-13 |
Araxes Pharma LLC |
Inhibiteurs covalents de k-ras g12c
|
WO2014143659A1
(fr)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Inhibiteurs covalents irréversibles de la gtpase k-ras g12c
|
WO2015000585A1
(fr)
|
2013-07-02 |
2015-01-08 |
Walter Sebald |
Mutéines de cytokines de la famille des récepteurs de la chaîne gamma conjuguées à un groupe non protéine
|
GB201312059D0
(en)
|
2013-07-05 |
2013-08-21 |
Univ Leuven Kath |
Novel GAK modulators
|
KR20160076519A
(ko)
|
2013-10-10 |
2016-06-30 |
아락세스 파마 엘엘씨 |
Kras g12c 억제제
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
GB201320729D0
(en)
*
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
ES2703826T3
(es)
|
2014-02-19 |
2019-03-12 |
Merck Patent Gmbh |
Inmunoterapia con IL-12 destinada al cáncer
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049524A1
(fr)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibiteurs de protéines mutantes kras g12c
|
WO2016049565A1
(fr)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions et procédés pour inhiber la ras
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
TW201702232A
(zh)
|
2015-04-10 |
2017-01-16 |
亞瑞克西斯製藥公司 |
經取代之喹唑啉化合物及其使用方法
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
MX2018000777A
(es)
|
2015-07-22 |
2018-03-23 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
WO2017058915A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines mutantes kras g12c
|
WO2017058768A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines kras portant la mutation g12c
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356339A1
(fr)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibiteurs de protéines mutantes kras g12c
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058807A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines kras portant la mutation g12c
|
JP7015059B2
(ja)
*
|
2015-11-16 |
2022-02-15 |
アラクセス ファーマ エルエルシー |
置換複素環式基を含む2-置換キナゾリン化合物およびその使用方法
|
WO2017100546A1
(fr)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Procédés de préparation de dérivés de quinazoléine
|
ES2954153T3
(es)
|
2015-12-22 |
2023-11-20 |
Regeneron Pharma |
Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
|
EP3400292B1
(fr)
|
2016-01-08 |
2020-08-26 |
Replimune Limited |
Utilisation d'un virus oncolytique pour traiter le cancer
|
KR20180103084A
(ko)
|
2016-02-03 |
2018-09-18 |
암젠 리서치 (뮌헨) 게엠베하 |
Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
|
EP3411404B1
(fr)
|
2016-02-03 |
2022-11-09 |
Amgen Research (Munich) GmbH |
Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
WO2017172979A1
(fr)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Composés quinazoline substitués et procédés d'utilisation
|
MA44507A
(fr)
|
2016-04-01 |
2019-02-06 |
Amgen Inc |
Récepteurs chimères de flt3 et leurs procédés d'utilisation
|
WO2017181420A1
(fr)
|
2016-04-22 |
2017-10-26 |
Immuno Vir Co., Limited |
Construction de vecteur obligatoire de virus herpès simplex oncolytiques (ohsv) et constructions pour le traitement du cancer
|
ES2863873T3
(es)
|
2016-05-18 |
2021-10-11 |
Mirati Therapeutics Inc |
Inhibidores de KRAS G12C
|
RU2758007C2
(ru)
|
2016-06-30 |
2021-10-25 |
Онкорус, Инк. |
Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
AU2017305335B2
(en)
|
2016-08-01 |
2021-11-18 |
Virogin Biotech Canada Ltd |
Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
|
EP3519402A1
(fr)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibiteurs de protéines mutantes kras g12c
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
RS62456B1
(sr)
|
2016-12-22 |
2021-11-30 |
Amgen Inc |
Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
CN110382483A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的n-杂环化合物及其使用方法
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
EP3788038B1
(fr)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
US11045484B2
(en)
|
2018-05-04 |
2021-06-29 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
WO2019217691A1
(fr)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Inhibiteurs de kras g12c pour le traitement du cancer
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
EP3802537A1
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc. |
Inhibiteurs de kras g12c pour le traitement du cancer
|
MX2020012261A
(es)
*
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
MA52939A
(fr)
|
2018-06-21 |
2021-04-28 |
Janssen Pharmaceutica Nv |
Composés inhibiteurs d'oga
|
EP3810586A1
(fr)
|
2018-06-21 |
2021-04-28 |
Janssen Pharmaceutica NV |
Composés inhibiteurs d'oga
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
CA3117222A1
(fr)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Inhibiteurs de kras g12c et leurs procedes d'utilisation
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
JP2022518591A
(ja)
|
2019-01-29 |
2022-03-15 |
博瑞生物医薬(蘇州)股▲分▼有限公司 |
複素環式化合物であるベンゾピリドンおよびその使用
|
EP3738593A1
(fr)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosage d'inhibiteur de kras pour le traitement de cancers
|
AU2020277398A1
(en)
|
2019-05-21 |
2021-12-09 |
Amgen Inc. |
Solid state forms
|
EP3972973A1
(fr)
|
2019-05-21 |
2022-03-30 |
Amgen Inc. |
Formes à l'état solide
|
WO2021081212A1
(fr)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer
|
US20230028414A1
(en)
|
2019-12-16 |
2023-01-26 |
Amgen Inc. |
Dosing regimen of kras g12c inhibitor
|